New data from the TANGO study demonstrate the non-inferior efficacy of dolutegravir/lamivudine (DTG/3TC) compared with a tenofovir alafenamide fumarate (TAF)-containing regimen of at least 3 drugs in virally suppressed individuals with HIV-1 infection.
“With HIV now considered a chronic condition and people living with HIV needing antiretroviral treatments for life, taking fewer medicines over a lifetime has become an important consideration for the community,” Kimberly Smith, MD, head of Global Research & Medical Strategy at ViiV Healthcare, said in a press release.
“The TANGO study was designed to answer the question, can a 2-drug regimen of dolutegravir/lamivudine maintain viral suppression as well as a TAF-containing regimen?”
The full 48-week results of the phase 3, randomized, open-label, active-controlled, multicenter study were presented at the 10th
IAS Conference on HIV Science (IAS 2019
The study enrolled 743 participants who were on a TAF-containing regimen with no history of virologic failure or resistance to nucleoside reverse transcriptase inhibitors or integrase inhibitors. The participants were randomized to switch to DTG/3TC or continue on the TAF-containing regimen through week 48.
The data presented at IAS 2019 indicate that the study met its primary end point for non-inferiority based on the proportion of participants with plasma HIV-1 RNA >
50 copies per mL at week 48.
The study found that switching to DTG/3TC was non-inferior to continuing a TAF-containing regimen (snapshot virologic failure: <1% vs <1%; adjusted difference: -0.3% [95% Confidence Interval =1.2, 0.7]).
Furthermore, it is reported that the proportion of patients with plasma HIV-1 RNA <50 c/mL was both high and similar in the treatment arms and demonstrated non-inferiority (93.2% [344 of 369] of participants in DTG/3TC compared with 93% [346 of 372] in the TAF-containing regimen arm).
At 48 weeks, 0 participants in the DTG/3TC group and 1 participant in the TAF-containing regimen group met confirmed virologic failure criteria; no resistance mutations were observed at failure.
Common adverse events (AEs) included nasopharyngitis, upper respiratory tract infections, and diarrhea. The percentage of participants who withdrew due to AEs was 4% in the DTG/3TC arm vs <1% in the TAF-containing regimen arm.
DTG/3TC was approved
by the US Food and Drug Administration on April 8, 2019. The approval made DTG/3TC (Dovato) the first FDA-approved 2-drug, fixed-dose, complete regimen for treatment-naïve adults with HIV.
“These data present evidence that a dolutegravir/lamivudine 2-drug regimen is as effective as a TAF-containing, 3-drug regimen for people living with HIV,” Smith concluded.
The study, “Switching to DTG+3TC fixed dose combination (FDC) is non-inferior to continuing a TAF-based regimen (TBR) in maintaining virologic suppression through 24 weeks (TANGO Study)
,” was presented in a late-breaking oral abstract session on July 24, 2019, at IAS 2019 in Mexico City, Mexico.
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.